Clinical trial
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to…
NCT00251641 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00251641 |
|---|---|
| Title | The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED) |
| Official title | An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | infliximab, methotrexate |
| Enrollment | 868 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 10, 2005 |
| Last update posted | May 10, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: